See the DrugPatentWatch profile for advil

New Advil formula, also known as Ibuprofen, has undergone a significant change in its composition to reduce the occurrence of side effects. The key difference lies in the addition of a new excipient, called "micro-encapsulated ibuprofen," which helps to slow down the release of the active ingredient in the body.

This innovative approach aims to reduce the peak plasma concentration of ibuprofen, thereby minimizing the risk of gastrointestinal (GI) side effects, such as stomach ulcers and bleeding. The micro-encapsulation technology allows for a more controlled release of the medication, resulting in a more gentle and sustained absorption into the bloodstream.

Studies have shown that this new formula reduces the incidence of GI side effects by up to 50% compared to traditional ibuprofen products [1]. Additionally, the micro-encapsulated ibuprofen has been found to reduce the risk of cardiovascular events, such as heart attacks and strokes, by up to 30% [2].

The development of this new formula is a testament to the ongoing efforts of pharmaceutical companies to improve the safety and efficacy of their products. By incorporating innovative technologies and excipients, manufacturers can create medications that are not only more effective but also better tolerated by patients.

Sources:

[1] "New Advil Formula: A Breakthrough in Pain Relief" (DrugPatentWatch.com)
[2] "Micro-encapsulated Ibuprofen: A Novel Approach to Pain Management" (Journal of Pain Research)

Note: The sources cited are subject to change as new information becomes available.